Basimglurant
id:
basimglurant-179-6471496
title:
Basimglurant
text:
Basimglurant (INN) is a negative allosteric modulator of the mGlu5 receptor which is under development by Roche and Chugai Pharmaceutical for the treatment of treatment-resistant depression and fragile X syndrome. As of November 2016, it has undergone phase II clinical trials for both of these indications. It was discovered in a medicinal chemistry effort conducted at Roche starting from the results of a small molecular weight compound library high-throughput screen based on a Ca21 mobilization
brand slug:
wiki
category slug:
encyclopedia
description:
Chemical compound
original url:
https://en.wikipedia.org/wiki/Basimglurant
date created:
2014-08-01T18:19:17Z
date modified:
2024-09-04T21:17:45Z
main entity:
{"identifier":"Q18209947","url":"https://www.wikidata.org/entity/Q18209947"}
image:
{"content_url":"https://upload.wikimedia.org/wikipedia/commons/5/5f/Basimglurant.svg","width":512,"height":248}
fields total:
13
integrity:
16